- Raised Series A led by Israel Innovation Authority, May 2024
- Raised Seed round led by FutuRx, Sep 2020
About
Selene Therapeutics is pioneering a new therapeutic strategy for treating refractory epilepsy by focusing on mitochondrial DHODH as a novel target to secure metabolic homeostasis of hyperexcitable hippocampal circuits. The company is part of the FuturX Bio-Accelerator, which was founded by J&J, Takeda, Orbimed Israel Partners, and later joined by Bayer, together with the Israeli Innovation Authority, and is supported by RMGP Biopharma Investment Fund. Its technology was licensed from Ramot, the commercial arm of Tel-Aviv University, from the lab of Professor Inna Slutsky. Selene Therapeutics aims to develop small molecule inhibitors to regulate neuronal activity. The company incorporates AI into its framework to transform the biological homeostatic loop into a dynamic, predictive control system, using deep learning algorithms to identify subtle patterns in neuronal noise and Reinforcement Learning agents to calculate precise DHODH blockade.
Funding history · 2 rounds · — total
Headcount over time
Q&A
- What is Selene Therapeutics' primary focus?
- Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by regulating neuronal activity to reduce the neuronal mean firing rate.
- What type of molecules is Selene Therapeutics developing?
- Selene Therapeutics aims to develop small molecules that act as inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme involved in cellular homeostatic processes.
- When was Selene Therapeutics founded?
- Selene Therapeutics was founded in September 2020.
- How many employees does Selene Therapeutics have?
- Selene Therapeutics has 1-10 employees.
- Which incubator is Selene Therapeutics part of?
- Selene Therapeutics is part of the FuturX biotech incubator in Ness Ziona, Israel.
- Who are the founders of Selene Therapeutics?
- The founders of Selene Therapeutics are Inna Slutsky and Neta Pessah.
- What was Selene Therapeutics' most recent funding event?
- In June 2024, Selene Therapeutics received funding from the Israel Innovation Authority.
- Which investors participated in Selene Therapeutics' October 2020 funding round?
- In October 2020, Selene Therapeutics received funding from RMGP Biopharma Investment Fund and FutuRx.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | futurx.co.il/cgi-sys/suspendedpage.cgi |
|---|---|
| linkedin.com/company/75889240 |
Identifiers & details
| Legal name | Selene Therapeutics Ltd. |
|---|---|
| Founded | 2020-9 |
| Employees (exact) | 1 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | futurx.co.il |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516254471 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-09-15 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 2 — annual_report (1), shares_capital (1) |
| Registered address | רמון אילן 2 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2025-07-21 | דו~ח שנתי |
| 2026-01-12 | הקצאת מניות |